Table 1 Baseline clinical characteristics and treatment history of patients in the training cohort.
Characteristics | Training cohort |
|---|---|
Gender | |
 Female | 615(57.5%) |
 Male | 454(42.5%) |
Age | |
  < 60 | 534 (50.0%) |
  ≥ 60 | 535 (50.0%) |
Race | |
 White | 845 (79.0%) |
 Other | 224 (21.0%) |
Marital status | |
 Married | 484 (45.3%) |
 Single/Unknown | 585 (54.7%) |
Site | |
 Salivary Gland | 546 (51.1%) |
 Pharynx and Larynx | 58 (5.4%) |
 Gum and Other Mouth | 186 (17.4%) |
 Tongue | 71 (6.6%) |
 Oral cavity | 50 (4.7%) |
 Nose, Nasal Cavity and Middle Ear | 158 (14.8%) |
Surgery | |
 No | 132 (12.3%) |
 Yes | 937 (87.7%) |
Radiation | |
 No/Unknown | 304 (28.4%) |
 Yes | 765 (71.6%) |
Chemotherapy | |
 No/Unknown | 910 (85.1%) |
 Yes | 159 (14.9%) |
T stage | |
 T1 | 286 (26.8%) |
 T2 | 261 (24.4%) |
 T3 | 196 (18.3%) |
 T4 | 326 (30.5%) |
N stage | |
 N0 | 906 (84.8%) |
 N1 | 89 (8.3%) |
 N2-N3 | 74 (6.9%) |
M stage | |
 M0 | 987 (92.3%) |
 M1 | 82 (7.7%) |
TNM stage | |
 I | 269 (25.2%) |
 II | 224 (21.0%) |
 III | 177 (16.6%) |
 IV | 399 (37.3%) |
Lymph Node dissection | |
 No | 628 (58.7%) |
 Yes | 441 (41.3%) |
Therapy | |
 Surgery + Radiotherapy | 684 (64.0%) |
 Surgery + Chemotherapy | 107 (10.0%) |
 Radiotherapy + Chemotherapy | 137 (12.8%) |
 Others | 141 (13.2%) |
Survival status | |
 Live | 684 (64.0%) |
 Dead | 385 (36.0%) |
